Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (CTRI/2026/09/117264) titled 'This Phase III study tests how safe and effective Evenamide is when added to regular treatment in people with schizophrenia' on Sept. 9.
Study Type: Interventional
Study Design:
Other Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label
Primary Sponsor: Newron Pharmaceuticals SpA
Condition:
Health Condition 1: F208- Other schizophrenia
Intervention:
Intervention1: Evenamide: A fixed dose of evenamide 30 mg, administered orally twice daily for a duration of 52 weeks
Control Intervention1: Not Applica...